A LinkedIn post from Dash Bio highlights the company’s planned participation in SLAS 2026 in Boston, where its Head of Automation & Laboratory Technology, Olga Seltser, is scheduled to speak. The session is described as focusing on requirements for scaling modern lab automation, including clean data, reliable integrations, and systems designed to evolve.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post further contrasts production-ready automation with superficial demonstrations, implying an emphasis on practical, scalable solutions for life sciences labs. For investors, this appearance may signal Dash Bio’s intent to position itself as a thought leader in lab automation, potentially strengthening its brand visibility among industry decision-makers and supporting future commercial and partnership opportunities.